Please sign in to follow a disease.

High-risk large B-cell lymphoma (LBCL)

Clinical trials for High-risk large B-cell lymphoma (LBCL) explained in plain language.

Never miss a new study

Get alerted when new High-risk large B-cell lymphoma (LBCL) trials appear

Sign up with your email to follow new studies for High-risk large B-cell lymphoma (LBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

CAR-T therapy takes on High-Risk lymphoma as First-Line treatment

Disease control Ongoing

This phase 3 trial is testing whether a single infusion of a patient's own genetically modified immune cells (CAR-T therapy, called Yescarta) works better than standard chemotherapy plus antibody treatment as the very first therapy for people with high-risk large B-cell lymphoma.…

Matched conditions: HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL)

Phase 3 • Sponsor: Kite, A Gilead Company • Aim: Disease control

Last updated Jun 27, 2026 12:08 UTC

High-risk large B-cell lymphoma (LBCL)

Get alerted when new High-risk large B-cell lymphoma (LBCL) trials appear

CAR-T therapy takes on High-Risk lymphoma as First-Line treatment